169 related articles for article (PubMed ID: 12057062)
21. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ
J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027
[TBL] [Abstract][Full Text] [Related]
22. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
23. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2014 Jan; 89(1):97-108. PubMed ID: 24464505
[TBL] [Abstract][Full Text] [Related]
24. Treatment of myelodysplastic syndromes.
Asano Y; Niho Y
Int J Clin Oncol; 2001 Apr; 6(2):74-9. PubMed ID: 11706753
[TBL] [Abstract][Full Text] [Related]
25. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
26. Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia.
Hasle H; Kerndrup G; Yssing M; Clausen N; Ostergaard E; Jacobsen N; Jacobsen BB
Leukemia; 1996 Aug; 10(8):1269-73. PubMed ID: 8709630
[TBL] [Abstract][Full Text] [Related]
27. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
[TBL] [Abstract][Full Text] [Related]
28. [The clinical analysis of allogeneic hematopoietic stem cell transplantation from human leukocyte antigen-identical siblings in 95 patients with myelodysplastic syndrome].
Zhao T; Huang X; Liu D; Wang J; Zhang X; Wang Y; Han W; Chen H; Chen Y; Wang F; Liu K; Xu L
Zhonghua Nei Ke Za Zhi; 2014 Feb; 53(2):89-93. PubMed ID: 24767157
[TBL] [Abstract][Full Text] [Related]
29. Intensive therapy for high-risk myelodysplastic syndromes and the biological significance of karyotype abnormalities.
Hiddemann W; Jahns-Streubel G; Verbeek W; Wörmann B; Haase D; Schoch C
Leuk Res; 1998 May; 22 Suppl 1():S23-6. PubMed ID: 9734696
[TBL] [Abstract][Full Text] [Related]
30. Hemopoietic stem cell transplantation for myelodysplastic syndrome.
Deeg HJ; Appelbaum FR
Curr Opin Oncol; 2000 Mar; 12(2):116-20. PubMed ID: 10750721
[TBL] [Abstract][Full Text] [Related]
31. Current challenges in therapy of myelodysplastic syndromes.
Estey EH
Curr Opin Hematol; 2003 Jan; 10(1):60-7. PubMed ID: 12483113
[TBL] [Abstract][Full Text] [Related]
32. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
33. Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors.
Oosterveld M; Muus P; Suciu S; Koller C; Verhoef G; Labar B; Wijermans P; Aul C; Fière D; Selleslag D; Willemze R; Gratwohl A; Ferrant A; Mandelli F; Cortes J; de Witte T; Estey E;
Leukemia; 2002 Sep; 16(9):1615-21. PubMed ID: 12200672
[TBL] [Abstract][Full Text] [Related]
34. Clinical use of hematopoietic growth factors in the myelodysplastic syndromes.
Ganser A; Karthaus M
Leuk Lymphoma; 1997 Dec; 26 Suppl 1():13-27. PubMed ID: 9570676
[TBL] [Abstract][Full Text] [Related]
35. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
36. High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure.
Pedersen-Bjergaard J; Pedersen M; Myhre J; Geisler C
Leukemia; 1997 Oct; 11(10):1654-60. PubMed ID: 9324285
[TBL] [Abstract][Full Text] [Related]
37. Clinical use of hematopoietic growth factors in patients with myelodysplastic syndromes.
Geissler RG; Schulte P; Ganser A
Int J Hematol; 1997 Jun; 65(4):339-54. PubMed ID: 9195774
[TBL] [Abstract][Full Text] [Related]
38. Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).
de Witte T; Suciu S; Meert L; Halkes C; Selleslag D; Bron D; Amadori S; Willemze R; Muus P; Baron F
Ann Hematol; 2015 Dec; 94(12):1981-9. PubMed ID: 26410352
[TBL] [Abstract][Full Text] [Related]
39. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies.
Darrington DL; Vose JM; Anderson JR; Bierman PJ; Bishop MR; Chan WC; Morris ME; Reed EC; Sanger WG; Tarantolo SR
J Clin Oncol; 1994 Dec; 12(12):2527-34. PubMed ID: 7989926
[TBL] [Abstract][Full Text] [Related]
40. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome.
Jädersten M; Malcovati L; Dybedal I; Della Porta MG; Invernizzi R; Montgomery SM; Pascutto C; Porwit A; Cazzola M; Hellström-Lindberg E
J Clin Oncol; 2008 Jul; 26(21):3607-13. PubMed ID: 18559873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
